AmbioPharm, Inc. (API), a full-service peptide and biopharmaceutical manufacturing company, is expanding its existing Aiken County operations. The expansion is projected to bring $18 million of new capital investment and lead to the creation of 100 jobs over the next five years.
“AmbioPharm continues to be grateful for the support that it receives from the state of South Carolina. Without this support, our business could not grow at the accelerated pace that our customers have come to expect,” said AmbioPharm, Inc. CFO Stephen Kiel.
AmbioPharm started its business in South Carolina in 2007 by establishing its company headquarters and downstream manufacturing operations in a 10,000-square-foot facility in the North Augusta Industrial Park. That same year, API also opened its Shanghai, China operations, which focuses on the synthesis, as well as the research and development, of pharmaceutical products. In 2014 and 2015, the company made major facility expansions to its Aiken County operations.
Located at 1024 Dittman Court in North Augusta, S.C., AmbioPharm will be constructing two additional freestanding buildings, totaling 50,000 square feet, and purchasing additional equipment. The Coordinating Council for Economic Development has approved job development credits related to this project.
“We want to thank AmbioPharm for today’s expansion announcement. Their continued growth is important to all the citizens of Aiken County, and the products they produce are important to the health and well-being of the country,” said Gary Stooksbury, chairman of the Board for the Economic Development Partnership (EDP), a non-profit public-private development corporation focused solely on serving the needs of new and existing businesses in the Aiken, Edgefield, and Saluda Region of South Carolina.